As GDP Slows, MNCs Should Still See Strong Growth In China – Analyst
This article was originally published in PharmAsia News
Executive Summary
Despite a slowdown in its overall economy, China remains an attractive strategic market for multinational pharma and device companies, analysts say, as all eyes focus on 2nd quarter earnings.